Physician profile
Luis E Luna
NPI 1922661776
$3,883.59
in general payments reported to CMS, 2019-2025
22 companies · $853 in 2025
The $853 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $808 · 2023: $975 · 2024: $655 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,482.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,137.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $463.12 | 2021-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $451.13 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $302.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $301.27 | 2021-2025 | Farxiga |
| Abbvie INC. | $273.54 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.73 | 2021-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $159.57 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $127.31 | 2021-2023 | Nuzyra |
| Janssen Pharmaceuticals, INC | $87.04 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.18 | 2023-2024 | Jardiance, Ofev |
| Pfizer INC. | $52.94 | 2024-2025 | |
| Phadia US INC. | $46.49 | 2024-2025 | Immunocap |
| Amarin Pharma, INC. | $41.56 | 2021 | |
| Sumitomo Pharma America, INC. | $36.22 | 2025 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.44 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $29.08 | 2023 | Rexulti |
| Astellas Pharma US INC | $26.32 | 2024 | Veozah |
| Mannkind Corporation | $24.33 | 2023 | Afrezza |
| Redhill Biopharma INC. | $17.34 | 2021 | |
| Merck Sharp & Dohme LLC | $16.00 | 2022 | |
| Dexcom, INC. | $15.64 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Luna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.